A national survey of adverse event for buccal midazolam as prehospital treatment

DOI
  • Hoshide Madoka
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Yamaguchi University, Ube, Yamaguchi
  • Korematsu Seigo
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Saitama Medical Center Saitama Medical University, Kawagoe, Saitama
  • Ito Susumu
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Tokyo Women’s Medical University, Tokyo
  • Shimokawa Shoko
    Medical Safety Committee, Japanese Society of Child Neurology Department of Neurosurgery, Kurume University School of Medicine, Kurume, Fukuoka
  • Miyata Rie
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Tokyo-kita Medical Center, Tokyo
  • Ihara Satoshi
    Medical Safety Committee, Japanese Society of Child Neurology Department of Neurosurgery, Tokyo Metropolitan Children’s Medical Center, Fuchu, Tokyo
  • Ishii Mitsuko
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Chiba Rehabilitation Center, Chiba
  • Watanabe Yoshihiro
    Medical Safety Committee, Japanese Society of Child Neurology Children’s Medical Center, Yokohama City University Medical Center, Yokohama, Kanagawa
  • Fukui Miho
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka
  • Sato Tatsuharu
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Nagasaki University Hospital, Nagasaki
  • Morimoto Noriko
    Medical Safety Committee, Japanese Society of Child Neurology Department of Otolaryngology, National Center for Child Health and Development, Tokyo
  • Miyamoto Yusaku
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Kanagawa
  • Mimaki Masakazu
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Teikyo University School of Medicine, Tokyo
  • Yamanaka Gaku
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics and Adolescent Medicine, Tokyo Medical University, Tokyo
  • Yamanouchi Hideo
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Saitama Medical University, Kawagoe, Saitama
  • Muramatsu Kazuhiro
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Jichi Medical University, Shimotsuke, Tochigi
  • Takeshima Yasuhiro
    Medical Safety Committee, Japanese Society of Child Neurology Department of Pediatrics, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo

Bibliographic Information

Other Title
  • 病院前治療におけるmidazolam口腔用液使用の有害事象に関する全国調査

Abstract

<p>  A questionnaire survey was conducted among members of the Japanese Society of Pediatric Neurology regarding adverse events with oral solution of midazolam (buccal MDL) used as prehospital treatment for status epilepticus. A total of 431 respondents were surveyed (12.0% responded). Of 580 patients treated with buccal MDL, 14 (2.4%) had adverse events (respiratory depression, falls and trauma due to dizziness, sedation for more than 1 hour). 7 of the 14 cases were due to respiratory depression. Respiratory depression should be considered as an adverse event when buccal MDL is administered for status epilepticus.</p>

Journal

  • NO TO HATTATSU

    NO TO HATTATSU 56 (2), 145-147, 2024

    The Japanese Society of Child Neurology

Keywords

Details 詳細情報について

  • CRID
    1390862389985242112
  • DOI
    10.11251/ojjscn.56.145
  • ISSN
    18847668
    00290831
  • Text Lang
    ja
  • Data Source
    • JaLC
  • Abstract License Flag
    Disallowed

Report a problem

Back to top